Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pertuzumab and Trastuzumab Variant #02 | ERBB2 | R 74 512 | 21d | — | — | — | — | — |
Trastuzumab emtansine monotherapy Variant #01 | ERBB2 | R 41 405 | 21d | ~7.4 mo | ~29.9 mo | ~11 | ~R 455 454 PFS proxy · indirect | 7 |
Neratinib monotherapy N/A - secondary systemic drug | ERBB2 | R 62 | 28d | — | — | — | — | 1 |
3 of 3 regimens shown